Immunogenicity of COVID ‐19 vaccines in patients with follicular lymphoma receiving frontline chemoimmunotherapy

Immunogenicity of COVID ‐19 vaccines in patients with follicular lymphoma receiving frontline chemoimmunotherapy

Summary: Immune responses to primary COVID‐19 vaccination were investigated in 58 patients with follicular lymphoma (FL) as part of the PETReA trial of frontline therapy (EudraCT 2016–004010‐10). COVID‐19 vaccines (BNT162b2 or ChAdOx1) were administered before, during or after cytoreductive treatmen...

Descrizione completa

Dettagli Bibliografici
Autori principali:	Lim, YJ, Ward, V, Brown, A, Phillips, E, Kronsteiner, B, Malone, T, Jennings, D, Healy, S, Longet, S, James, T, Thomson, P, Farrell, L, Oates, M, Jackson, R, Morrison, A, Burns, M, Carroll, M, Klenerman, P, Turtle, L, Naisbitt, D, Rhodes, M, Robinson, K, Gatto, S, Young, M, Eyre, TA, Eyre, DW, Dunachie, S, Barnes, E
Natura:	Journal article
Lingua:	English
Pubblicazione:	Wiley 2024

Documenti analoghi

P1095: COVID-19 VACCINE RESPONSES IN FOLLICULAR LYMPHOMA: DETERMINANTS OF HUMORAL AND CELLULAR IMMUNITY IN THE PETREA TRIAL OF FRONTLINE CHEMOIMMUNOTHERAPY
di: Yeong Jer Lim, et al.
Pubblicazione: (2023-08-01)

Interim Positron Emission Tomography During Frontline Chemoimmunotherapy for Follicular Lymphoma
di: Reid W. Merryman, et al.
Pubblicazione: (2023-02-01)

Follicular Lymphoma in Chile in the Adult Public Cancer Program: The Impact of Chemoimmunotherapy
di: María Elena Cabrera, et al.
Pubblicazione: (2024-09-01)

Venous thromboembolism in primary central nervous system lymphoma during frontline chemoimmunotherapy
di: Hiu Lam Agnes Yuen, et al.
Pubblicazione: (2020-08-01)

Symptomatic Follicular Lymphoma: Complete Remission After Chemoimmunotherapy with Bendamustine–Rituximab
di: Wulyo Rajabto, et al.
Pubblicazione: (2024-04-01)

Two Follicular Dendritic Cell Sarcoma (FDCS) patients treated with Chemoimmunotherapy
di: Berksoy Sahin, et al.
Pubblicazione: (2024-05-01)

Relationship between BCL2 mutations and follicular lymphoma outcome in the chemoimmunotherapy era
di: Cristina Correia, et al.
Pubblicazione: (2023-05-01)

Predictors of benefits from frontline chemoimmunotherapy in stage IV non-small-cell lung cancer: a meta-analysis
di: Hazem E. El-Osta, et al.
Pubblicazione: (2019-12-01)

Survival in elderly follicular lymphoma patients who receive frontline chemo-immunotherapy.
di: Griffiths, R, et al.
Pubblicazione: (2010)

Skeletal muscle radio-density is an independent predictor of response and outcomes in follicular lymphoma treated with chemoimmunotherapy.
di: Michael P Chu, et al.
Pubblicazione: (2015-01-01)

mRNA vaccination drives differential mucosal neutralizing antibody profiles in naïve and SARS-CoV-2 previously-infected individuals
di: Stephanie Longet, et al.
Pubblicazione: (2022-09-01)

A phase 2 study of frontline pembrolizumab in follicular lymphoma
di: Carrie Ho, et al.
Pubblicazione: (2024-12-01)

Low CCL19 expression is associated with adverse clinical outcomes for follicular lymphoma patients treated with chemoimmunotherapy
di: Yu Zhou, et al.
Pubblicazione: (2021-09-01)

Quantitative study of Clostridium difficile transmission using extensive epidemiological data and whole genome sequencing
di: Eyre, DW
Pubblicazione: (2013)

EZH2 mutations at diagnosis in follicular lymphoma: a promising biomarker to guide frontline treatment
di: C. Martínez-Laperche, et al.
Pubblicazione: (2022-09-01)

Early progression beyond first‐line chemoimmunotherapy in follicular lymphoma: Insights from a Fondazione Italiana Linfoma (FIL) study
di: Alberto Bavieri, et al.
Pubblicazione: (2024-12-01)

Correction: EZH2 mutations at diagnosis in follicular lymphoma: a promising biomarker to guide frontline treatment
di: C. Martínez-Laperche, et al.
Pubblicazione: (2022-11-01)

Nanoparticle-Mediated Synergistic Chemoimmunotherapy for Cancer Treatment
di: Lang X, et al.
Pubblicazione: (2024-05-01)

THE CHEMOIMMUNOTHERAPY BASED ON DENDRITIC CELLS AND CISPLATIN IN EXPERIMENT
di: Gorbach O. I., et al.
Pubblicazione: (2014-08-01)

Age- and sex-specific differences in immune responses to BNT162b2 COVID-19 and live-attenuated influenza vaccines in UK adolescents
di: Cecilia Jay, et al.
Pubblicazione: (2023-10-01)

Letter: Chemoimmunotherapy of adult acute leukaemia.
di: Peto, R, et al.
Pubblicazione: (1975)

Application of Neoadjuvant Chemoimmunotherapy in Resectable NSCLC
di: Huaiyong WANG, et al.
Pubblicazione: (2023-11-01)

MAPK signaling regulates the efficacy of chemoimmunotherapy
di: François Ghiringhelli
Pubblicazione: (2022-12-01)

P1163: OUTCOMES OF HIGH-RISK LARGE B-CELL LYMPHOMA TREATED WITH STANDARD OF CARE CHEMOIMMUNOTHERAPY: A NON-RANDOMIZED COMPARISON TO FRONTLINE CAR-T CELL THERAPY
di: O. Albanyan, et al.
Pubblicazione: (2022-06-01)

Rituximab maintenance significantly reduces early follicular lymphoma progressions in patients treated with frontline R‐CHOP
di: Vít Procházka, et al.
Pubblicazione: (2020-07-01)

Teaching your children responsibility /
di: 424418 Eyre, Linda, et al.
Pubblicazione: (1994)

A model for effects of adaptive immunity on tumor response to chemotherapy and chemoimmunotherapy.
di: Robertson-Tessi, M, et al.
Pubblicazione: (2015)

Use of lateral flow devices allows rapid triage of patients with SARS-CoV-2 on admission to hospital
di: Young, BC, et al.
Pubblicazione: (2021)

Advances in Lipid-Based Nanoparticles for Cancer Chemoimmunotherapy
di: Tianqi Wang, et al.
Pubblicazione: (2021-04-01)

Targeted delivery of liposomal chemoimmunotherapy for cancer treatment
di: Yusheng Liu, et al.
Pubblicazione: (2022-10-01)

Outcomes of patients with Richter transformation who received no prior chemoimmunotherapy for their CLL
di: Adam S. Kittai, et al.
Pubblicazione: (2025-02-01)

Hash-based core genome multilocus sequencing typing for Clostridium difficile
di: Eyre, DW, et al.
Pubblicazione: (2019)

182 Peripheral immunological features as predictors of breast cancer chemoimmunotherapy response
di: Justin M Balko, et al.
Pubblicazione: (2023-11-01)

Antibiotic Use and Survival in Patients With Late-Stage NSCLC Treated With Chemoimmunotherapy
di: Emanuela Taioli, MD, PhD, et al.
Pubblicazione: (2024-12-01)

Hyaluronic acid-bilirubin nanomedicine-based combination chemoimmunotherapy
di: Yonghyun Lee, et al.
Pubblicazione: (2023-08-01)

Fabrication of An Immunostimulatory Supramolecular Nanomedicine for Potent Cancer Chemoimmunotherapy
di: Xinyang Yu, et al.
Pubblicazione: (2023-11-01)

Nanoparticles for Chemoimmunotherapy Against Triple-Negative Breast Cancer
di: Liu S, et al.
Pubblicazione: (2022-11-01)

On the frontlines
di: Daniel Vila, et al.
Pubblicazione: (2022-08-01)

Impact of shipping temperature on cell viability and T cell responses to bacterial antigens [version 1; peer review: 2 approved]
di: Susanna J. Dunachie, et al.
Pubblicazione: (2023-04-01)

On the dynamics of tidal streams in the Milky Way galaxy
di: Eyre, A, et al.
Pubblicazione: (2010)